Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Vienna - Delayed Quote EUR

Boston Scientific Corporation (BSXC.VI)

Compare
83.80
+0.80
+(0.96%)
At close: April 15 at 5:32:34 PM GMT+2

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Michael F. Mahoney Chairman, President & CEO 4.71M 19.75M 1965
Mr. Joseph M. Fitzgerald Executive VP & Group President of Cardiology 1.94M 6.58M 1964
Mr. Jeffrey B. Mirviss M.B.A. Executive VP & President of Peripheral Interventions 1.32M 2.85M 1966
Mr. Arthur Crosswell Butcher Executive VP and Group President of MedSurg & Asia Pacific 1.5M 831.82k 1971
Mr. John Bradley Sorenson Executive Vice President of Global Operations -- -- 1968
Ms. Emily M. Woodworth Senior VP, Global Controller & Chief Accounting Officer -- -- 1978
Ms. Jodi Euerle Eddy Senior VP and Chief Information & Digital Officer -- -- 1973
Mr. Jonathan R Monson Senior VP of Investor Relations -- -- --
Mr. Vance R. Brown J.D. Senior VP, General Counsel & Corporate Secretary -- -- 1970
Ms. Mary Beth Moynihan Senior VP of Market Access & Chief Marketing Officer -- -- 1968

Boston Scientific Corporation

300 Boston Scientific Way
Marlborough, MA 01752-1234
United States
508 683 4000 https://www.bostonscientific.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
53,000

Description

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Corporate Governance

Boston Scientific Corporation’s ISS Governance QualityScore as of April 1, 2025 is 8. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 8; Compensation: 5.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

April 23, 2025 at 12:30 PM UTC

Boston Scientific Corporation Earnings Date

Recent Events